ALE.P03

DRUG2 trials

Sponsors

Alentis Therapeutics AG

Conditions

Advanced or Metastatic Solid TumorsCervical Squamous Cell CarcinomaColorectal CancerIntrahepatic CholangiocarcinomaSquamous Non-small-cell Lung CancerUrothelial Carcinoma

Phase 1

A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

RecruitingNCT07169734

Alentis Therapeutics AGCervical Squamous Cell Carcinoma, Colorectal Cancer, Intrahepatic Cholangiocarcinoma +2

Start: 2025-08-26End: 2029-10-04Target: 180Updated: 2026-07-02

A Phase I/II, Open-Label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy in Adult Patients with Selected Advanced or Metastatic CLDN1+ Solid Tumors

Not yet recruitingCTIS2025-521441-24-00

Alentis Therapeutics AGAdvanced or Metastatic Solid Tumors

Target: 77Updated: 2026-01-27